Your browser doesn't support javascript.
loading
Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial.
Mandeville, Henry C; Bisogno, Gianni; Minard-Colin, Veronique; Alaggio, Rita; Ben-Arush, Myriam; Chargari, Cyrus; Coppadoro, Beatrice; Craigie, Ross; Devalck, Christine; Ferman, Sima; Ferrari, Andrea; Glosli, Heidi; Alvaro, Raquel Hladun; Hol, Marinka; Mudry, Peter; Orbach, Daniel; Albiac, Monica Ramos; Merks, Johannes H M; Jenney, Meriel E M.
Afiliação
  • Mandeville HC; The Royal Marsden Hospital and The Institute of Cancer Research, Surrey, UK.
  • Bisogno G; Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy.
  • Minard-Colin V; Department of Pediatric and Adolescent Oncology, INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Alaggio R; Pathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
  • Ben-Arush M; Ruth Rappaport Children's Hospital, Rambam Medical Center, Joan and Sanford Weill Pediatric Hematology Oncology and Bone Marrow Transplantation Division, Haifa, Israel.
  • Chargari C; Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Coppadoro B; Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy.
  • Craigie R; Department of Paediatric Surgery, Royal Manchester Children's Hospital, Manchester, UK.
  • Devalck C; Hôpital Universitaire des Enfants Reine Fabiola ULB, Brussels, Belgium.
  • Ferman S; Pediatric Oncology Department, National Cancer Institute, Rio de Janeiro, Brazil.
  • Ferrari A; Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
  • Glosli H; Centre for Rare Disorders, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
  • Alvaro RH; Department of Pediatric Oncology and Haematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Hol M; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Mudry P; Pediatric Oncology, Department University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic.
  • Orbach D; SIREDO Oncology Center, Institut Curie, PSL University, Paris, France.
  • Albiac MR; Department of Radiotherapy, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Merks JHM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Jenney MEM; Children's Hospital for Wales, Heath Park, Cardiff, UK.
Cancer ; 2024 Jul 26.
Article em En | MEDLINE | ID: mdl-39058728
ABSTRACT

BACKGROUND:

The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS). PATIENTS AND

METHODS:

Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m2 ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m2 ifosfamide) ± radiotherapy. Delayed primary tumor excision was considered for IRS III tumors. The primary end points were event-free survival (EFS) and overall survival (OS).

RESULTS:

From October 2005 to December 2016, 359 evaluable patients were recruited orbit, 164 (45.7%); head and neck nonparameningeal, 77 (21.4%); and genitourinary non-bladder/prostate, 118 (32.9%). EFS and OS were 77.4% (95% confidence interval [CI], 72.5-81.6) and 93.5% (95% CI, 90.1-95.8), respectively. Lower dose alkylator chemotherapy and radiotherapy achieved 5-year OS of 93.7% but the difference with higher dose alkylator chemotherapy +/- radiotherapy was not significant (p = 0.8003). Adjuvant radiotherapy improved EFS with 5-year estimates of 84.7% versus 65.2% for nonirradiated (p < .0001), but not OS (p = .9298). Omitting radiotherapy for orbital tumors reduced OS (5-year was 87.1% vs. 97.3% for irradiated, p = .0257). Following R0 resection (n = 60), radiotherapy did not significantly improve EFS or OS.

CONCLUSIONS:

Radiotherapy for local tumor control allows for reduction of cumulative dose of alkylators in EpSSG standard risk subgroup C RMS patients. The omission of radiotherapy did not affect OS in all patients except those with orbital RMS and was associated with inferior EFS.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article